Verastem | VSTM - Selling And Administration Expenses

Stock Price
5.82
Daily Change
-0.02 -0.34%
Monthly
-14.29%
Yearly
-2.51%
Q1 Forecast
5.64

Verastem reported $12.28M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alaunos Therapeutics USD 585K 260K Sep/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Curis USD 4.79M 100K Jun/2024
Cytokinetics USD 158.75M 93.03M Sep/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Laboratory Of America USD 552.4M 26.9M Sep/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025
Verastem USD 12.28M 2.06M Sep/2024